Immunai has signed three major pharma deals in six months. The reason keeps coming back to the same thing: data that cannot be replicated in a single R&D cycle.
A new AI analysis of a negative Alzheimer's trial raises questions about whether conventional clinical trials are missing patients who could still benefit from treatment.
Scientists showed that a trio of medications successfully cleared the virus in a rhesus macaque infant model. Clinical testing in human infants could move quickly.